OGEN Oragenics Inc

Price (delayed)

$0.525

Market cap

$2.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.44

Enterprise value

-$1.5M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 5

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also ...

Highlights
The debt has dropped by 100% since the previous quarter and by 100% year-on-year
OGEN's EPS has dropped by 107% year-on-year but it has surged by 51% since the previous quarter
Oragenics's net income has decreased by 2.6% from the previous quarter but it has increased by 2.1% YoY
The company's quick ratio has shrunk by 55% QoQ
Oragenics's equity has decreased by 41% from the previous quarter

Key stats

What are the main financial stats of OGEN

OGEN stock price

How has the Oragenics stock price performed over time
Intraday
-2.78%
1 week
-1.48%
1 month
-2.78%
1 year
-51.39%
YTD
-32.97%
QTD
-9.58%

Financial performance

How have Oragenics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.47M
Net income
-$10.08M
Gross margin
N/A
Net margin
N/A
OGEN's operating income is down by 10% year-on-year and by 9% since the previous quarter
Oragenics's net income has decreased by 2.6% from the previous quarter but it has increased by 2.1% YoY

Price vs fundamentals

How does OGEN's price correlate with its fundamentals

Growth

What is Oragenics's growth rate over time

Valuation

What is Oragenics stock price valuation
P/E
N/A
P/B
0.65
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OGEN's EPS has dropped by 107% year-on-year but it has surged by 51% since the previous quarter
The P/B is 80% less than the 5-year quarterly average of 3.3 but 30% more than the last 4 quarters average of 0.5
Oragenics's equity has decreased by 41% from the previous quarter

Efficiency

How efficient is Oragenics business performance
OGEN's ROE has soared by 97% YoY and by 19% from the previous quarter
OGEN's ROA has soared by 65% year-on-year and by 7% since the previous quarter
The company's return on invested capital rose by 25% QoQ

Dividends

What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OGEN.

Financial health

How did Oragenics financials performed over time
The total assets has soared by 157% YoY but it has contracted by 27% from the previous quarter
The total liabilities has plunged by 57% YoY but it has grown by 39% from the previous quarter
The debt is 100% smaller than the equity
OGEN's debt to equity has shrunk by 100% QoQ but it has soared by 100% YoY
The debt has dropped by 100% since the previous quarter and by 100% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.